Association of ANA positivity (≥1/160) with various outcomes in the CARMEN registry (215 tested patients)
| Outcomes . | Total (N = 215) . | Positive ANAs (n = 92) . | Negative ANAs (n = 123) . | p . |
|---|---|---|---|---|
| Age, median (Q1-Q3), y | 64.0 (41.0-79.0) | 66.0 (44.0-83.5) | 60.0 (39.0-76.0) | .07 |
| Male sex, n (%) | 107 (49.8) | 44 (47.8) | 63 (51.2) | .6 |
| History of autoimmune disease, n (%) | 34 (15.8) | 17 (18.5) | 17 (13.8) | .3 |
| Bleeding at ITP diagnosis, overall, n (%) | 126 (58.6) | 53 (57.6) | 73 (59.4) | .8 |
| Cutaneous bleeding at ITP diagnosis, n (%) | 112 (52.1) | 47 (51.1) | 65 (52.8) | .8 |
| Mucosal bleeding at ITP diagnosis, n (%) | 56 (26.1) | 23 (25.0) | 33 (26.8) | .8 |
| Serious bleeding at ITP diagnosis, n (%)* | 13 (6.1) | 7 (7.6) | 6 (4.9) | .4 |
| Platelet count at ITP diagnosis, median (Q1-Q3), ×109/L | 18.0 (5.0-50.0) | 18.0 (5.0-49.5) | 18.0 (6.0-51.0) | .9 |
| Response to first-line treatment, n (%) | 136 (80.0) | 62 (83.8) | 74 (77.1) | .3 |
| Complete response to first-line treatment, n (%) | 101 (59.8) | 49 (67.1) | 52 (54.2) | .2 |
| Thrombosis during follow-up, n (%) | 14 (6.5) | 8 (8.7) | 6 (4.9) | .3 |
| Venous thrombosis during follow-up, n (%) | 9 (4.2) | 5 (5.4) | 4 (3.2) | .5 |
| Arterial thrombosis during follow-up, n (%) | 6 (2.8) | 4 (4.3) | 2 (1.6) | .4 |
| Outcomes . | Total (N = 215) . | Positive ANAs (n = 92) . | Negative ANAs (n = 123) . | p . |
|---|---|---|---|---|
| Age, median (Q1-Q3), y | 64.0 (41.0-79.0) | 66.0 (44.0-83.5) | 60.0 (39.0-76.0) | .07 |
| Male sex, n (%) | 107 (49.8) | 44 (47.8) | 63 (51.2) | .6 |
| History of autoimmune disease, n (%) | 34 (15.8) | 17 (18.5) | 17 (13.8) | .3 |
| Bleeding at ITP diagnosis, overall, n (%) | 126 (58.6) | 53 (57.6) | 73 (59.4) | .8 |
| Cutaneous bleeding at ITP diagnosis, n (%) | 112 (52.1) | 47 (51.1) | 65 (52.8) | .8 |
| Mucosal bleeding at ITP diagnosis, n (%) | 56 (26.1) | 23 (25.0) | 33 (26.8) | .8 |
| Serious bleeding at ITP diagnosis, n (%)* | 13 (6.1) | 7 (7.6) | 6 (4.9) | .4 |
| Platelet count at ITP diagnosis, median (Q1-Q3), ×109/L | 18.0 (5.0-50.0) | 18.0 (5.0-49.5) | 18.0 (6.0-51.0) | .9 |
| Response to first-line treatment, n (%) | 136 (80.0) | 62 (83.8) | 74 (77.1) | .3 |
| Complete response to first-line treatment, n (%) | 101 (59.8) | 49 (67.1) | 52 (54.2) | .2 |
| Thrombosis during follow-up, n (%) | 14 (6.5) | 8 (8.7) | 6 (4.9) | .3 |
| Venous thrombosis during follow-up, n (%) | 9 (4.2) | 5 (5.4) | 4 (3.2) | .5 |
| Arterial thrombosis during follow-up, n (%) | 6 (2.8) | 4 (4.3) | 2 (1.6) | .4 |
*Intracranial, gastrointestinal bleeding, or macroscopic hematuria.